Binding Database

BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 772K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

13 articles for DW Bonhaus

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Cmpds

Data

Article Title

Organization

43

2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.

Syntex Research

22

Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists.

Neuropore Therapies

23

1-sulfonyl piperidine derivatives as modulators of prokineticin receptors

Takeda Pharmaceutical

13

Radiolabeled compounds

Takeda Pharmaceutical

150

4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity

Virostatics

24

Dipeptidyl nitrile inhibitors of Cathepsin L.

AstraZeneca

24

Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics.

Gsk

16

Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs.

Absolute Science

26

Investigation on the role of the tetrazole in the binding of thiotetrazolylacetanilides with HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases.

Boehringer Ingelheim (Canada)

24

Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase.

Valeant Pharmaceuticals Research and Development

5

Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase.

Vertex Pharmaceuticals

16

Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.

Bristol Myers Squibb